JAMA Oncology

Authors on the study included, from left, Jennifer Pietenpol, PhD, Melinda Sanders, MD, Brian Lehmann, PhD, Vandana Abramson, MD, and Yu Shyr, PhD. (photo by Donn Jones)
December 15, 2023

Clinical trial shows efficacy for atezolizumab combined with carboplatin

By Tom Wilemon
November 17, 2022

Surgery for hereditary breast cancer

Similar rates of bilateral mastectomy in women with inherited mutations in high- and moderate-penetrance genes raises concerns about possible overtreatment of some patients, Vanderbilt researchers report.

By Leigh MacMillan
November 11, 2022

Study finds inherited link to appendix cancer

A Vanderbilt study is the first to show inherited risk factors for appendiceal cancer.

By Tom Wilemon
Studies by Andrew Glazer, PhD, Giovanni Davogustto, MD, and colleagues found that genetic testing with information from electronic health records can reveal undiagnosed heart rhythm disorders.
April 28, 2022

Studies combine genetic testing, electronic health records to find undiagnosed diseases

Combining genetic testing with information from electronic health records revealed undiagnosed heart rhythm disorders and new conditions associated with inherited cancer gene mutations.

By Leigh MacMillan
December 9, 2021

Prostate cancer treatment regret

Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity.

By Leigh MacMillan
April 15, 2021

Method proposed to correct misinterpretations of long-term survival rates for immunotherapies

Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.

By Tom Wilemon
March 25, 2021

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
By Tom Wilemon
March 18, 2021

Vanderbilt research played key role in new lung screen guidelines

The U.S. Preventive Services Task Force (USPSTF) has formally recommended two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.
By Tom Wilemon
March 9, 2021

Study incorporates genetics with smoking history to identify high-risk smokers for lung cancer screening

A study by Vanderbilt researchers that analyzed both smoking history and genetic risk variants for lung cancer supports modifying current guidelines to include additional smokers for lung cancer screening.
By Tom Wilemon
July 23, 2020

Criteria for lung cancer screens may be expanded

The U.S. Preventive Services Task Force (USPSTF) is recommending two changes that will nearly double the number of people eligible for lung cancer screening by lowering the age from 55 to 50 and reducing the number of smoking history pack years from 30 to 20.
By Tom Wilemon
October 28, 2019

High fiber, yogurt diet associated with lower lung cancer risk

A diet high in fiber and yogurt is associated with a reduced risk for lung cancer, according to a study by Vanderbilt University Medical Center researchers.
By Tom Wilemon
October 17, 2019

Study finds men have higher mortality rate after breast cancer diagnosis

A new study shows men with breast cancer are more likely to die than their female counterparts, across all stages of disease.
By Tom Wilemon
September 5, 2019

Study backs genetic testing for all metastatic breast cancer patients

By Tom Wilemon